Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine

Drug Discovery Today

Volumn 13, Issue 17-18, 2008, Pages 748-759

  Eckelman, William C ^a   Reba, Richard C ^b   Kelloff, Gary J ^c  

^a Molecular Tracer LLC   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 [2 (DIMETHYLAMINOMETHYLPHENYLTHIO)] 5 IODOPHENYLAMINE I 125; 3 [3 (3 FLUOROPROPYL)THIO] 1,2,5 (THIADIAZOL 4 YL) 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE F 18; 3 METHYLSPIPERONE C 11; 3 QUINUCLIDINYL 4 IODOBENZILATE I 123; 3' DEOXY 3' FLUOROTHYMIDINE F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ACETIC ACID C 11; ALBUMIN F 18; BIOLOGICAL MARKER; CARFENTANIL C 11; CHOLINE C 11; CHOLINE F 18; CYCLOFOXY F 18; DOPAMINE TRANSPORTER; FALLYPRIDE F 18; FLUMAZENIL C 11; FLUORINE; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYOPHENYLALANINE F 18; IBRITUMOMAB TIUXETAN; IMATINIB; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; N METHYL (2 IODOPHENOXY) 3 PHENYLPROPYLAMINE I 125; NEOGLYCOALBUMIN TC 99M; NORADRENALIN TRANSPORTER; RACLOPRIDE C 11; SEROTONIN TRANSPORTER; TOSITUMOMAB I 131; TRACER; TRANSFERRIN F 18; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; CELL PROLIFERATION; DISEASE COURSE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; INFLAMMATION; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; GENETIC DISEASES, INBORN; HUMANS; MICE; MICE, KNOCKOUT; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 51249087509     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.05.009     Document Type: Review

References (71)

1. Mukhtar M. Evolution of biomarkers: drug discovery to personalized medicine. Drug Discov. Today 10 (2005) 1216-1218
2. Ross J.S., and Ginsburg G.S. Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discov. Today 7 (2002) 859-864
3. Sadee W., and Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14 Spec No. 2 (2005) R207-R214
4. Nunn A.D. Molecular imaging and personalized medicine: an uncertain future. Cancer Biother. Radiopharm. 22 (2007) 722-739
5. Myers W.G. Georg Charles de Hevesy: the father of nuclear medicine. J. Nucl. Med. 20 (1979) 590-594
6. Hevesy G., and Paneth F. A Manual of Radioactivity. 2nd edn (1938), Oxford University Press
7. Ehrlich C. Experimental Researches on Specific Therapy. On Immunity with Special Reference to the Relationship between Distribution and Action of Antigens. Royal Institute of Public Health (1908), Lewis p. 107
8. Witkop B. Proc. Am. Philos. Soc. 143 (1999) 540-557
9. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28 (1977) 897-916
10. Meikle S.R., et al. Complementary molecular imaging technologies: high resolution SPECT, PET and MRI. Drug Discov. Today: Technol. 3 (2006) 187-194
11. Miller J.C., and Thrall J.H. Clinical molecular imaging. J. Am. Coll. Radiol. 1 Suppl. (2004) 14-23
12. Therasse P., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. (Bethesda) 92 (2000) 205-216
13. Eckelman W.C. Radiolabeling with 99mTc to study high capacity and low capacity biochemical systems. Eur. J. Nucl. Med. 22 (1995) 249-263
14. Weissleder R., et al. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. Am. J. Roentgenol. 155 (1990) 1161-1167
15. Vera D.R., et al. A molecular receptor-binding contrast agent for magnetic resonance imaging of the liver. Acad. Radiol. 2 (1995) 497-506
16. Bolo N.R., et al. Fluorodeoxyglucose brain metabolism studied by NMR and PET. Ann. N. Y. Acad. Sci. 508 (1987) 451-459
17. Brix G., et al. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study. Nucl. Med. Biol. 23 (1996) 897-906
18. Weissleder R., et al. In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6 (2000) 351-355
19. Carrasquillo J.A. Radioimmunoscintigraphy with polyclonal or monoclonal antibodies. In: Zalutsky M.R. (Ed). Antibodies in Radiodiagnosis and Radiotherapy (1989), CRC Press 169-198
20. In: Eckelman W.C. (Ed). Receptor Binding Radiotracers Vols. I and II (1982), CRC Press
21. Eckelman W.C., et al. Receptor binding radiotracers: a class of potential radiopharmaceuticals. J. Nucl. Med. 20 (1979) 350-357
22. Kung M.P., and Kung H.F. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl. Med. Biol. 32 (2005) 673-678
23. Selikson Gibson R.E., et al. Calculation of binding isotherms when ligand and receptor are in different volumes of distribution. Anal. Biochem. 108 (1980) 64-71
24. 18F]-fallypride in monkeys using a PET multiple-injection protocol. J. Cereb. Blood Flow Metab. 24 (2004) 309-322
25. Zambrowicz B.P., and Sands A.T. Knockouts model the 100 best-selling drugs - will they model the next 100?. Nat. Rev. Drug Discov. 2 (2003) 38-51
26. Eckelman W.C. Finding the right targeted probe for the right target for the right disease. In: Mazzi U. (Ed). Proceedings of the Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine. Servizi Grafici Editoriali snc, Padova, Italy (2006) 657-664
27. 18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow. Synapse 50 (2003) 151-163
28. Eckelman W.C. The use of gene-manipulated mice in the validation of receptor binding radiotracer. Nucl. Med. Biol. 30 (2003) 851-860
29. Laruelle M., et al. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27 (2002) 287-299
30. Logan J., et al. Simplifications in analyzing positron emission tomography data: effects on outcome measures. Nucl. Med. Biol. 34 (2007) 743-756
31. Carson R.E. Mathematical modeling and compartmental analysis. In: Harbert J., Neumann R., and Eckelman W. (Eds). Nuclear Medicine: Diagnosis and Therapy (1996), Thieme Press, New York 167-194
32. Patlak C.S., et al. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 31 (1983) 1-7
33. Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl. Med. Biol. 30 (2003) 833-844
34. Hoh C.K. Clinical use of FDG PET. Nucl. Med. Biol. 34 (2007) 737-742
35. Passchier J., et al. Measuring drug-related receptor occupancy with positron emission tomography. Methods 27 (2002) 278-286
36. Eckelman W.C. Imaging of muscarinic receptors in the central nervous system. Curr. Pharm. Des. 12 (2006) 3901-3913
37. Sams-Dodd F. Drug discovery: selecting the optimal approach. Drug Discov. Today 11 (2006) 465-472
38. Blasberg R.G. In vivo molecular-genetic imaging: multi-modality nuclear and optical combinations. Nucl. Med. Biol. 30 (2003) 879-888
39. Serganova I., and Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl. Med. Biol. 32 (2005) 763-780
40. Eckelman W.C., et al. Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?. Nucl. Med. Biol. 32 (2005) 657-662
41. Krohn K.A., et al. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl. Med. Biol. 32 (2005) 663-671
42. Kelloff G.J., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 11 (2005) 7967-7985
43. Lecchi M., et al. Current concepts on imaging in radiotherapy. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 821-837
44. 18F]FDG PET in clinical oncology. Lancet Oncol. 8 (2007) 822-830
45. 18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 33 (2006) 287-294
46. 131I]iodobenzylguanidine. J. Nucl. Med. 21 (1980) 349-353
47. Raffel D.M., and Wieland D.M. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl. Med. Biol. 28 (2001) 541-559
48. Rufini V., et al. Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36 (2006) 228-247
49. Fani M., and Maecke H.R. The status of diagnostic and therapeutic targeting of somatostatin receptor-positive tumours. In: Mazzi U. (Ed). Proceedings of the Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine. Servizi Grafici Editoriali snc, Padova, Italy (2006) 263-276
50. Iten F., et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin. Cancer Res. 13 (2007) 6696-6702
51. Wehrmann C., et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother. Radiopharm. 22 (2007) 406-416
52. American College of Radiology. Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Practice Guidelines and Technical Standards 2003 (2003), American College of Radiology 503-510
53. Tran T., et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug. Chem. 18 (2007) 1956-1964
54. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur. J. Cancer 43 (2007) 2046-2051
55. 111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. Int. J. Mol. Med. 20 (2007) 397-404
56. Olafsen T., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65 (2005) 5907-5916
57. Nowell P.C. Discovery of the Philadelphia chromosome: a personal perspective. J. Clin. Invest. 117 (2007) 2033-2035
58. Kil K.E., et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl. Med. Biol. 34 (2007) 153-163
59. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 39 (2003) 2012-2020
60. Demetri G.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
61. Holdsworth C.H., et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am. J. Roentgenol. 189 (2007) W324-W330
62. Grimpen F., et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol. 6 (2005) 724-727
63. Su H., et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 12 (2006) 5659-5667
64. 18F-FDG PET. J. Nucl. Med. 47 (2006) 793-796
65. Dimitrakopoulou-Strauss A., et al. A recent application of fluoro-18-deoxyglucose positron emission tomography, treatment monitoring with a mammalian target of rapamycin inhibitor: an example of a patient with a desmoplastic small round cell tumor. Hell. J. Nucl. Med. 10 (2007) 77-79
66. Smith-Jones P.M., et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. 22 (2004) 701-706
67. Cohen R.M., et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49 (2003) 150-156
68. Balaban E. Eugenics and individual phenotypic variation: to what extent is biology a predictive science?. Science 11 (1998) 331-356
69. Cantor C.R. The use of genetic SNPs as new diagnostic markers in preventive medicine. Ann. N. Y. Acad. Sci. 1055 (2005) 48-57
70. El-Deiry W.S., et al. Imaging and oncologic drug development. J. Clin. Oncol. 4 (2006) 3261-3273
71. Ng J.H., and Ilag L.L. Streamlining drug development: finding the right drug against the right target to treat the right disease. Drug Discov. Today 9 (2004) 59